If you have been reading about lipolysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
The remaining energy to initiate fission can be supplied by two other mechanisms: one of these is more kinetic energy of the incoming neutron, which is increasingly able to fission a fissionable heavy nucleus as it exceeds a kinetic energy of 1 MeV or more (so-called fast neutrons). Such high energy neutrons are able to fission 238U directly (see thermonuclear weapon for application, where the fast neutrons are supplied by nuclear fusion). However, this process cannot happen to a great extent in a nuclear reactor, as too small a fraction of the fission neutrons produced by any type of fission have enough energy to efficiently fission 238U. (For example, neutrons from thermal fission of 235U have a mean energy of 2 MeV, a median energy of 1.6 MeV, and a mode of 0.75 MeV, and the energy spectrum for fast fission is similar.) Among the heavy actinide elements, however, those isotopes that have an odd number of neutrons (such as 235U with 143 neutrons) bind an extra neutron with an additional 1 to 2 MeV of energy over an isotope of the same element with an even number of neutrons (such as 238U with 146 neutrons). This extra binding energy is made available as a result of the mechanism of neutron pairing effects, which itself is caused by the Pauli exclusion principle, allowing an extra neutron to occupy the same nuclear orbital as the last neutron in the nucleus.
The quantitative allergy blood result can help determine what a patient is allergic to, predict and monitor disease progression, estimate the risk of a severe reaction, and explain cross-reactivity. A low total IgE level is not adequate to rule out sensitization to commonly inhaled allergens. Statistical methods, such as ROC curves, predictive value calculations, and likelihood ratios have been used to examine the relationship of various testing methods to each other. These methods have shown that patients with high total IgE have a high probability of allergic sensitization, but further investigation with allergy tests for specific IgE antibodies for a carefully chosen set of allergens is often warranted. Laboratory methods to measure specific IgE antibodies for allergy testing include enzyme-linked immunosorbent assay, radioallergosorbent test, fluorescent enzyme immunoassay, and chemiluminescence immunoassay.
The first class of adenylyl cyclases occur in many bacteria including E. coli (as CyaA P00936 [unrelated to the Class II enzyme]). This was the first class of AC to be characterized. It was observed that E. coli deprived of glucose produce cAMP that serves as an internal signal to activate expression of genes for importing and metabolizing other sugars. cAMP exerts this effect by binding the transcription factor CRP, also known as CAP. Class I AC's are large cytosolic enzymes (~100 kDa) with a large regulatory domain (~50 kDa) that indirectly senses glucose levels. As of 2012, no crystal structure is available for class I AC. Some indirect structural information is available for this class. It is known that the N-terminal half is the catalytic portion, and that it requires two Mg2+ ions. S103, S113, D114, D116 and W118 are the five absolutely essential residues. The class I catalytic domain (Pfam PF12633) belongs to the same superfamily (Pfam CL0260) as the palm domain of DNA polymerase beta (Pfam PF18765). Aligning its sequence onto the structure onto a related archaeal CCA tRNA nucleotidyltransferase (PDB: 1R89) allows for assignment of the residues to specific functions: γ-phosphate binding, structural stabilization, DxD motif for metal ion binding, and finally ribose binding.
Sources: en.wikipedia.org
== Quarter-finals == The draw for the quarter-finals took place on 1 March 2023. This round included one team from the fourth tier, the lowest-ranked team remaining in the competition: Grimsby Town. Grimsby were the first fourth-tier side to reach the quarter-finals since Cambridge United in 1990.
== Diversity == There are a large number of different odor receptors, with as many as 2,000 in the mammalian genome which, depending on the species represents up to 5% of the coding-genes in the genome. However, not all of these potential odor receptor genes are expressed and functional. According to an analysis of data derived from the Human Genome Project, humans have approximately 400 functional genes coding for olfactory receptors, and the remaining 600 candidates are pseudogenes. The reason for the large number of different odor receptors is to provide a system for discriminating between as many different odors as possible. Even so, each odor receptor does not detect a single odor. Rather each individual odor receptor is broadly tuned to be activated by a number of similar odorant structures. Analogous to the immune system, the diversity that exists within the olfactory receptor family allows molecules that have never been encountered before to be characterized. However, unlike the immune system, which generates diversity through in-situ recombination, every single olfactory receptor is translated from a specific gene; hence the large portion of the genome devoted to encoding OR genes. Furthermore, most odors activate more than one type of odor receptor. Since the number of combinations and permutations of olfactory receptors is very large, the olfactory receptor system is capable of detecting and distinguishing between a very large number of odorant molecules.
=== 2007 === Reconstitution of a Cambodian traditional wood kiln 40 000 Litres. This kiln has mobilized 15 people for two months + 5000h work. The original kiln has been discovered at Phnom Kulen. 1st International Khmer Ceramics festival & Conference. The conference is held at the CKS center for Khmer study.
Glutathione has antioxidant properties since the thiol group in its cysteine moiety is a reducing agent and can be reversibly oxidized and reduced. In cells, glutathione is maintained in the reduced form by the enzyme glutathione reductase and in turn reduces other metabolites and enzyme systems, such as ascorbate in the glutathione-ascorbate cycle, glutathione peroxidases and glutaredoxins, as well as reacting directly with oxidants. Due to its high concentration and its central role in maintaining the cell's redox state, glutathione is one of the most important cellular antioxidants. In some organisms glutathione is replaced by other thiols, such as by mycothiol in the Actinomycetes, bacillithiol in some gram-positive bacteria, or by trypanothione in the Kinetoplastids. A derivative of glutathione, glutathione hydropersulfide, operates as an abundant radical-trapping antioxidant with greater potency against free radical oxidation than glutathione itself.
Sources: en.wikipedia.org
In 1923–24 inventor Harry Grindell Matthews repeatedly claimed to have built a device that projected energy over long ranges and attempted to sell it to the War Office, but it was deemed to be fraudulent. His attempts spurred on many other inventors to contact the British military with claims of having perfected some form of the fabled electric or radio "death ray". Some turned out to be frauds and none turned out to be feasible. Around the same time, a series of stories suggested another radio weapon was being developed in Germany. The stories varied, with one common thread being a death ray, and another that used the signals to interfere with an engine's ignition system to cause the engine to stall. One commonly repeated story involved an English couple who were driving in the Black Forest on holiday and had their car fail in the countryside. They claimed they were approached by soldiers who told them to wait while they conducted a test, and were then able to start their engine without trouble when the test was complete. This was followed shortly thereafter by a story in a German newspaper with an image of a large radio antenna that had been installed on Feldberg in the same area. Although highly skeptical about claims of engine-stopping rays and death rays, the Air Ministry could not ignore them as they were theoretically possible. If such systems could be built, it might render bombers useless. If this were to happen, the night bomber deterrent might evaporate overnight, leaving the UK open to attack by Germany's ever-growing air fleet.
Bread is a significant part of German cuisine, with German bakeries producing about 600 main types of bread and 1,200 types of pastries and rolls (Brötchen). German cheeses account for about 22% of all cheese produced in Europe. Germans produce their ubiquitous sausages in almost 1,500 varieties, including Bratwurst and Weißwurst. The national alcoholic drink is beer. Germany's beer consumption per capita stood at 110 litres (24 imp gal; 29 US gal) in 2013 and remains among the highest in the world. German beer purity regulations date back to the 16th century. Wine has become popular in many parts of the country, especially near the German wine regions. In 2019, Germany was the ninth-largest wine producer in the world. The 2018 Michelin Guide awarded eleven restaurants in Germany three stars, giving the country a cumulative total of 300 stars.
To correct a defect of the nasal lining of the upper two-thirds of the nose, the wound dimensions (length, width, depth) determine the technique. A nasal-lining defect of less than 5 mm in diameter can be closed primarily, with sutures. A nasal-lining defect 5–15 mm in diameter can be closed with a random transposition flap harvested from a nasal area that remains protected, either by the nasal bones or by the upper lateral cartilages; and the flap donor-site can be healed by secondary intention, re-epithelialisation. For a mucosa defect greater than 15 mm in diameter, the indicated correction is a superiorly based "trap door" septal mucosal flap, grafted to the roof of the nasal septum. (c) Nasal tip defect The width of the human nasal-tip ranges 20–30 mm; the average width of the nasal tip, measured between the two alar lobules, is approximately 25 mm.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.